Synthesis, Anticancer Activity and Molecular Docking Studies of Hybrid Benzimidazole-1,3,4-Oxadiazol-2-N-Alkyl/Aryl Amines

References

• M. Laverdiere, J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, “Estimates of Worldwide Burden of Cancer in 2008: GLOBOCAN 2008,” International Journal of Cancer 127, no. 12 (2010): 2893–917.
   PubMed Web of Science ®Google Scholar
• Cancer incidence and mortality worldwide, Lyon. International Agency for Research on Cancer (2011). (IARC Cancer Base No. 10).
   Google Scholar
• Preetha Anand, Ajaikumar B. Kunnumakkara, Ajaikumar B. Kunnumakara, Chitra Sundaram, Kuzhuvelil B. Harikumar, Sheeja T. Tharakan, Oiki S. Lai, Bokyung Sung, and Bharat B. Aggarwal, “Cancer is a Preventable Disease That Requires Major Lifestyle Changes,” Pharmaceutical Research 25, no. 9 (2008): 2097–116.
   PubMed Web of Science ®Google Scholar
• Global Cancer Observatory, International Agency for Research on Cancer, WHO ( 2018) Cancer today – Data visualization tools for exploring the global cancer burden in 2018.
   Google Scholar
• M. L. Rothenberg, D. P. Carbone, and D. H. Johnson, “Improving the Evaluation of New Cancer Treatments: Challenges and Opportunities,” Nature Reviews. Cancer 3, no. 4 (2003): 303–9.
   PubMed Web of Science ®Google Scholar
• G. Housman, S. Byler, S. Heerboth, K. Lapinska, M. Longacre, N. Snyder, and S. Sarkar, “Drug Resistance in Cancer: An Overview,” Cancers 6, no. 3 (2014): 1769–92. https://dx.doi.org/10.3390/cancers6031769.
   PubMed Web of Science ®Google Scholar
• T. Iwamoto, “Clinical Application of Drug Delivery Systems in Cancer Chemotherapy: Review of the Efficacy and Side Effects of Approved Drugs,” Biological & Pharmaceutical Bulletin 36, no. 5 (2013): 715–8.
   PubMed Web of Science ®Google Scholar
• J. J. Monsuez, J. C. Charniot, N. Vignat, and J. Y. Artigou, “Cardiac Side-Effects of Cancer Chemotherapy,” International Journal of Cardiology 144, no. 1 (2010): 3–15.
   PubMed Web of Science ®Google Scholar
• D. Kumar, G. Patel, A. K. Chavers, K. H. Chang, and K. Shah, “Synthesis of Novel 1,2,4-Oxadiazoles and Analogues as Potential Anticancer Agents,” European Journal of Medicinal Chemistry 46, no. 7 (2011): 3085–92.
   PubMed Web of Science ®Google Scholar
• G. M. Cragg, P. G. Grothaus, and D. J. Newman, “Impact of Natural Products on Developing New anti-Cancer Agents,” Chemical Reviews 109, no. 7 (2009): 3012–43.
   PubMed Web of Science ®Google Scholar
• G. Gonzales, and L. Valerio, “Medicinal Plants from Peru: A Review of Plants as Potential Agents against Cancer,” Anti-Cancer Agents in Medicinal Chemistry 6, no. 5 (2006): 429–44.
   PubMedGoogle Scholar
• J. Mendelsohn, and J. Baselga, “The EGF Receptor Family as Targets for Cancer Therapy,” Oncogene 19, no. 56 (2000): 6550–65.
   PubMed Web of Science ®Google Scholar
• I. Panchal, A. G. Devgirkar, A. D. Patel, A. Nagani, and C. Lad, “Molecular Modelling, Synthesis and Biological Evaluation of Novel Benzimidazole Derivatives for the Treatment of Breast Cancer,” Current Chinese Chemistry 1, no. 1 (2021): 11–20.
   Google Scholar
• L. F. Hennequin, A. P. Thomas, C. Johnstone, E. S. Stokes, P. A. Ple, J. J. Lohmann, D. J. Ogilvie, M. Dukes, S. R. Wedge, J. O. Curwen, et al. “Design and Structure-Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors,” Journal of Medicinal Chemistry 42, no. 26 (1999): 5369–89.
   PubMed Web of Science ®Google Scholar
• R. Abonia, E. Cortés, B. Insuasty, J. Quiroga, M. Nogueras, and J. Cobo, “Synthesis of Novel 1,2,5-Trisubstituted Benzimidazoles as Potential Antitumor Agents,” European Journal of Medicinal Chemistry 46, no. 9 (2011): 4062–70.
   PubMed Web of Science ®Google Scholar
• N. R. T. Gowda, C. V. Kavitha, K. K. Chiruvella, O. Joy, K. S. Rangappa, and S. C. Raghavan, “Synthesis and Biological Evaluation of Novel 1-(4-Methoxyphenethyl)-1H-Benzimidazole-5-Carboxylic Acid Derivatives and Their Precursors as Antileukemic Agents,” Bioorganic & Medicinal Chemistry Letters 19, no. 16 (2009): 4594–600.
   PubMed Web of Science ®Google Scholar
• Q. Guan, C. Han, D. Zuo, M. Zhai, Z. Li, Q. Zhang, Y. Zhai, X. Jiang, K. Bao, Y. Wu, et al. “Synthesis and Evaluation of Benzimidazole Carbamates Bearing Indole Moieties for Antiproliferative and Antitubulin Activities,” European Journal of Medicinal Chemistry 87, (2014): 306–15.
   PubMed Web of Science ®Google Scholar
• H. M. Refaat, “Synthesis and Anticancer Activity of Some Novel 2-Substituted Benzimidazole Derivatives,” European Journal of Medicinal Chemistry 45, no. 7 (2010): 2949–56.
   PubMed Web of Science ®Google Scholar
• S. Tahlan, S. Kumar, S. Kakkar, and B. Narasimhan, “Benzimidazole Scaffolds as Promising Antiproliferative Agents: A Review,” BMC Chemistry 13, (2019): 66.
   Web of Science ®Google Scholar
• Y. K. Yoon, M. A. Ali, A. C. Wei, T. S. Choon, H. Osman, K. Parang, and A. N. Shirazi, “Synthesis and Evaluation of Novel Benzimidazole Derivatives as Sirtuin Inhibitors with Antitumor Activities,” Bioorganic & Medicinal Chemistry 22, no. 2 (2014): 703–10.
   PubMed Web of Science ®Google Scholar
• A. Romero-Castro, I. León-Rivera, L. C. Ávila-Rojas, G. Navarrete-Vázquez, and A. Nieto-Rodríguez, “Synthesis and Preliminary Evaluation of Selected 2-Aryl-5(6)-Nitro- 1H-Benzimidazole Derivatives as Potential Anticancer Agents,” Archives of Pharmacal Research 34, no. 2 (2011): 181–9.
   PubMed Web of Science ®Google Scholar
• G. S. Kumar, B. Rathnakar, S. Gattu, S. S. Jadav, N. Rameshwar, S. Boyapati, and M. Satyanarayana, “Design, Synthesis and Evaluation of Hybrid 2-Heteroaryl Benzimidazole Chalcone Derivatives as Anticancer Agents,” Letters in Organic Chemistry 17, (2020). https://doi.org/10.2174/1570178617999201106140951.
   Google Scholar
• M. Subramanyam, R. Sreenivasulu, R. Gundla, M. V. B. Rao, and K. P. Rao, “Synthesis, Biological Evaluation and Docking Studies of 1,3,4-Oxadiazole Fused Benzothiazole Derivatives for Anticancer Drugs,” Letters in Drug Design & Discovery 15, no. 12 (2018): 1299–307.
   Web of Science ®Google Scholar
• S. Marri, R. Kakkerla, M. P. S. Murali Krishna, and M. Venkat Rajam, “Synthesis and Antimicrobial Evaluation of Isoxazole-Substituted 1,3,4-Oxadiazoles,” Heterocyclic Communications 24, no. 5 (2018): 285–92.
   Web of Science ®Google Scholar
• R. V. Patel, P. K. Patel, P. Kumari, D. P. Rajani, and K. H. Chikhalia, “Synthesis of Benzimidazolyl-1,3,4-Oxadiazol-2ylthio-N-Phenyl (Benzothiazolyl) Acetamides as Antibacterial, Antifungal and Antituberculosis Agents,” European Journal of Medicinal Chemistry 53, (2012): 41–51.
   PubMed Web of Science ®Google Scholar
• M. T. Abdel-Aal, W. A. El-Sayed, S. M. El-Kosy, and E. S. H. El-Ashry, “Synthesis and Antiviral Evaluation of Novel 5-(N-Aryl-Aminomethyl-1,3,4-Oxadiazol-2-yl)Hydrazines and Their Sugars, 1,2,4-Triazoles, Tetrazoles and Pyrazolyl Derivatives,” Archiv Der Pharmazie 341, no. 5 (2008): 307–13.
   PubMed Web of Science ®Google Scholar
• A. Husain, and M. Ajmal, “Synthesis of Novel 1,3,4-Oxadiazole Derivatives and Their Biological Properties,” Acta Pharmaceutica 59, (2009): 223–33.
   PubMed Web of Science ®Google Scholar
• B. S. Holla, R. Gonsalves, and S. Shenoy, “Synthesis and Antibacterial Studies of a New Series of 1,2-Bis(1,3,4-Oxadiazol-2-yl)Ethanes and 1,2-Bis(4-Amino-1,2,4-Triazol-3-yl)Ethanes,” European Journal of Medicinal Chemistry 35, no. 2 (2000): 267–71.
   PubMed Web of Science ®Google Scholar
• S. Bhati, V. Kumar, S. Singh, and J. Singh, “Synthesis, Characterization, Antimicrobial, anti-Tubercular, Antioxidant Activities and Docking Simulations of Derivatives of 2-(Pyridin-3-yl)-1Hbenzo[d]Imidazole and 1,3,4-Oxadiazole Analogy,” Letters in Drug Design & Discovery 17, no. 8 (2020): 1047–59.
   Web of Science ®Google Scholar
• R. Yan, Z.-M. Zhang, X.-Y. Fang, Y. Hu, and H.-L. Zhu, “Synthesis, Molecular Docking and Biological Evaluation of 1,3,4-Oxadiazole Derivatives as Potential Immunosuppressive Agents,” Bioorganic & Medicinal Chemistry 20, no. 4 (2012): 1373–9.
   PubMed Web of Science ®Google Scholar
• W. McCoull, M. S. Addie, A. M. Birch, S. Birtles, L. K. Buckett, R. J. Butlin, S. S. Bowker, S. Boyd, S. Chapman, R. D. M. Davies, et al. “Identification, Optimisation and in Vivo Evaluation of Oxadiazole DGAT-1 Inhibitors for the Treatment of Obesity and Diabetes,” Bioorganic & Medicinal Chemistry Letters 22, no. 12 (2012): 3873–8.
   PubMed Web of Science ®Google Scholar
• A. D. White, M. W. Creswell, A. W. Chucholowski, C. J. Blankley, M. W. Wilson, R. F. Bousley, A. D. Essenburg, K. L. Hamelehle, B. R. Krause, R. L. Stanfield, et al. “Heterocyclic Ureas: Inhibitors of Acyl-CoA: Cholesterol O-Acyltransferase as Hypocholesterolemic Agents,” Journal of Medicinal Chemistry 39, no. 22 (1996): 4382–95.
   PubMed Web of Science ®Google Scholar
• Y. Ducharme, M. Blouin, C. Brideau, A. Châteauneuf, Y. Gareau, E. L. Grimm, H. Juteau, S. Laliberté, B. MacKay, F. Massé, et al. “The Discovery of Setileuton, a Potent and Selective 5-Lipoxygenase Inhibitor,” ACS Medicinal Chemistry Letters 1, no. 4 (2010): 170–4.
   PubMed Web of Science ®Google Scholar
• N. Jain, S. K. Kashaw, R. K. Agrawal, A. Gupta, and A. Soni, “Synthesis, Anticonvulsant and Neurotoxic Activity of Some New 2,5-Disubstituted-1,3,4-Oxadiazoles,” Medicinal Chemistry Research 20, no. 9 (2010): 1696–703.
   Web of Science ®Google Scholar
• Z. Xiang, A. D. Thompson, J. T. Brogan, M. L. Schulte, B. J. Melancon, D. Mi, L. M. Lewis, B. Zou, L. Yang, R. Morrison, et al. “The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease,” ACS Chemical Neuroscience 2, no. 12 (2011): 730–42.
   PubMed Web of Science ®Google Scholar
• X. Ouyang, E. L. Piatnitski, V. Pattaropong, X. Chen, H.-Y. He, A. S. Kiselyov, A. Velankar, J. Kawakami, M. Labelle, L. Smith, I. I, et al. “Oxadiazole Derivatives as a Novel Class of Antimitotic Agents: Synthesis, Inhibition of Tubulin Polymerization, and Activity in Tumor Cell Lines,” Bioorganic & Medicinal Chemistry Letters 16, no. 5 (2006): 1191–6.
   PubMed Web of Science ®Google Scholar
• H. Ullah, F. Rahim, M. Taha, R. Hussain, A. Wadood, M. Nawaz, Z. Wahab, Kanwal, and K. M. Khan, “Synthesis, in Vitro α-Glucosidase Inhibitory Potential and Molecular Docking Studies of 2-Amino-1,3,4-Oxadiazole Derivatives,” Medicinal Chemistry 16, (2020) : 724–34.
   PubMed Web of Science ®Google Scholar
• K. Chudgar, S. N. Shah, and R. A. Vora, “Mesogenic Semicarbazones and Amino Oxadiazoles-I,” Molecular Crystals and Liquid Crystals Incorporating Nonlinear Optics 172, no. 1 (1989): 51–6.
   Web of Science ®Google Scholar
• R. Katikireddy, R. Kakkerla, M. P. S. M. Krishna, G. Durgaiah, and Y. N. Reddy, “Design, Synthesis, Anticancer Activity and Molecular Docking Studies of 2,5-Disubstituted-1,3,4-Oxadiazoles Containing Benzimidazole Moiety,” Letters in Organic Chemistry 17, no. 12 (2020): 959–68.
   Web of Science ®Google Scholar
• M. Rashid, A. Husain, and R. Mishra, “Synthesis of Benzimidazoles Bearing Oxadiazole Nucleus as Anticancer Agents,” European Journal of Medicinal Chemistry 54, (2012) : 855–66.
   PubMed Web of Science ®Google Scholar
• M. Rashid, A. Husain, R. Mishra, S. Karim, S. Khan, M. Ahmad, N. Al-Wabel, A. Husain, A. Ahmad, and S. A. Khan, “Design and Synthesis of Benzimidazoles Containing Substituted Oxadiazole, Thiadiazole and Triazolo-Thiadiazines as a Source of New Anticancer Agents,” Arabian Journal of Chemistry 12, (2019) : 3202–24.
   Web of Science ®Google Scholar
• M. J. Akhtar, A. A. Siddiqui, A. A. Khan, Z. Ali, R. P. Dewangan, S. Pasha, and M. S. Yar, “Design, Synthesis, Docking and QSAR Study of Substituted Benzimidazole Linked Oxadiazole as Cytotoxic Agents, EGFR and erbB2 Receptor Inhibitors,” European Journal of Medicinal Chemistry 126, (2017) : 853–69.
   PubMed Web of Science ®Google Scholar
• B. Meunier, “Hybrid Molecules with a Dual Mode of Action: Dream or Reality?,” Accounts of Chemical Research 41, no. 1 (2008): 69–77.
   PubMed Web of Science ®Google Scholar
• S. S. Mishra, and P. Singh, “Hybrid Molecules: The Privileged Scaffolds for Various Pharmaceuticals,” European Journal of Medicinal Chemistry 124, (2016) : 500–36.
   PubMed Web of Science ®Google Scholar
• M. Botta, S. Armaroli, D. Castagnolo, G. Fontana, P. Pera, and E. Bombardelli, “Synthesis and Biological Evaluation of New Taxoids Derived from 2-Deacetoxytaxinine J,” Bioorganic & Medicinal Chemistry Letters 17, no. 6 (2007): 1579–83.
   PubMed Web of Science ®Google Scholar
• O. Trott, and A. J. Olson, “AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading,” Journal of Computational Chemistry 31, no. 2 (2010): 455–61.
   PubMed Web of Science ®Google Scholar
• G. M. Morris, R. Huey, W. Lindstrom, M. F. Sanner, R. K. Belew, D. S. Goodsell, and A. J. Olson, “AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility,” Journal of Computational Chemistry 30, no. 16 (2009): 2785–91.
   PubMed Web of Science ®Google Scholar
• R. G. Kurumbail, A. M. Stevens, J. K. Gierse, J. J. McDonald, R. A. Stegeman, J. Y. Pak, D. Gildehaus, J. M. Iyashiro, T. D. Penning, K. Seibert, et al. “Structural Basis for Selective Inhibition of Cyclooxygenase-2 by anti-Inflammatory Agents,” Nature 384, no. 6610 (1996): 644–8.
   PubMed Web of Science ®Google Scholar
• R. Katikireddy, R. Kakkerla, M. P. S. M. Krishna, G. Durgaiah, Y. N. Reddy, and M. Satyanarayana, “Synthesis and Biological Evaluation of (E)-N′-Benzylidene-7-Methyl-2-Propyl-1H-Benzo[d] Imidazole-5-Carbohydrazides as Antioxidant, anti-Inflammatory and Analgesic Agents,” Heterocyclic Communications 25, no. 1 (2019): 27–38.
   Web of Science ®Google Scholar
• J. H. Park, Y. Liu, M. A. Lemmon, and R. Radhakrishnan, “Erlotinib Binds Both Inactive and Active Conformations of the EGFR Tyrosine Kinase Domain,” The Biochemical Journal 448, no. 3 (2012): 417–23.
   PubMed Web of Science ®Google Scholar